Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SERGE A JABBOUR

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1235152315
CMS profile
147048
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$282,671.23

236 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $168,690.38 136
Janssen Pharmaceuticals, Inc $60,732.72 52
Boehringer Ingelheim Thai Ltd $18,640.52 3
Novo Nordisk Inc $14,464.91 34
SANOFI-AVENTIS U.S. LLC $12,382.51 6
Eli Lilly and Company $4,480.79 3
GlaxoSmithKline, LLC. $3,220.00 1
Mannkind Corporation $59.40 1

Page 3 of 5; records 101–150 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SERGE A JABBOUR

NPI 1235152315 · CMS profile ID 147048

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235152315?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SERGE A JABBOUR, NPI 1235152315, CMS profile ID 147048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235152315?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SERGE A JABBOUR, NPI 1235152315, CMS profile ID 147048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235152315?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SERGE A JABBOUR, NPI 1235152315, CMS profile ID 147048, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 236 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1235152315?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

236 matching records · $282,671.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 236 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 236.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $41.4810/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685158315 CMS
AstraZeneca Pharmaceuticals LP $19.3610/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685370851 CMS
AstraZeneca Pharmaceuticals LP $55.3010/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685420961 CMS
AstraZeneca Pharmaceuticals LP $292.3310/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685511251 CMS
AstraZeneca Pharmaceuticals LP $20.7410/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685589501 CMS
AstraZeneca Pharmaceuticals LP $404.1710/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685765291 CMS
AstraZeneca Pharmaceuticals LP $66.5010/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685778423 CMS
AstraZeneca Pharmaceuticals LP $50.2510/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685807643 CMS
AstraZeneca Pharmaceuticals LP $118.5110/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685947163 CMS
Janssen Pharmaceuticals, Inc $98.0410/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762799 CMS
AstraZeneca Pharmaceuticals LP $4,300.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685045847 CMS
AstraZeneca Pharmaceuticals LP $83.5709/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685395843 CMS
AstraZeneca Pharmaceuticals LP $809.8409/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685700869 CMS
AstraZeneca Pharmaceuticals LP $4,300.0009/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685767867 CMS
AstraZeneca Pharmaceuticals LP $4,300.0009/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685858463 CMS
AstraZeneca Pharmaceuticals LP $646.8609/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685220343 CMS
AstraZeneca Pharmaceuticals LP $4,300.0009/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685423457 CMS
AstraZeneca Pharmaceuticals LP $94.1809/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685829899 CMS
AstraZeneca Pharmaceuticals LP $1,128.2209/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685327859 CMS
AstraZeneca Pharmaceuticals LP $100.0209/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685654031 CMS
AstraZeneca Pharmaceuticals LP $912.6809/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685577057 CMS
AstraZeneca Pharmaceuticals LP $125.0009/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685971337 CMS
AstraZeneca Pharmaceuticals LP $2,150.0009/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685823855 CMS
AstraZeneca Pharmaceuticals LP $4,300.0009/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685262937 CMS
AstraZeneca Pharmaceuticals LP $108.1709/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685238835 CMS
AstraZeneca Pharmaceuticals LP $850.8009/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685887429 CMS
AstraZeneca Pharmaceuticals LP $2,150.0009/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685201831 CMS
AstraZeneca Pharmaceuticals LP $3,200.0009/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685945595 CMS
Novo Nordisk Inc $5.0509/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682890451 CMS
AstraZeneca Pharmaceuticals LP $124.9909/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685857557 CMS
AstraZeneca Pharmaceuticals LP $35.9609/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685604365 CMS
AstraZeneca Pharmaceuticals LP $125.8909/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685805475 CMS
AstraZeneca Pharmaceuticals LP $125.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685311137 CMS
Eli Lilly and Company $2,100.0008/27/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658144355 CMS
AstraZeneca Pharmaceuticals LP $4,300.0008/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685926711 CMS
AstraZeneca Pharmaceuticals LP $4,300.0008/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685321579 CMS
Novo Nordisk Inc $22.6908/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674604635 CMS
Novo Nordisk Inc $5,015.0008/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750695707 CMS
AstraZeneca Pharmaceuticals LP $163.7308/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685090311 CMS
AstraZeneca Pharmaceuticals LP $683.4408/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685187189 CMS
AstraZeneca Pharmaceuticals LP $23.9408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685192455 CMS
AstraZeneca Pharmaceuticals LP $65.1308/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685571459 CMS
AstraZeneca Pharmaceuticals LP $81.1708/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685872473 CMS
Novo Nordisk Inc $4.8708/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682466263 CMS
Janssen Pharmaceuticals, Inc $2,895.0008/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762781 CMS
Janssen Pharmaceuticals, Inc $2,895.0008/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762785 CMS
Novo Nordisk Inc $34.7408/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750695703 CMS
Janssen Pharmaceuticals, Inc $575.0508/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762767 CMS
Janssen Pharmaceuticals, Inc $91.6708/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762771 CMS
Janssen Pharmaceuticals, Inc $2,895.0007/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658762759 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $282,671.23 236
PY2020 $147,045.60 195
PY2021 $159,798.28 176
PY2022 $115,954.70 188
PY2023 $137,857.59 169
PY2024 $190,373.50 186
PY2025 $163,286.21 155

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $77.45 1
PY2025 Principal investigator $476,151.14 40
PY2024 Principal investigator $317,757.71 494
PY2023 Principal investigator $201,483.04 14
PY2022 Recipient $18,953.00 2
PY2022 Principal investigator $76,003.00 7
PY2021 Recipient $110.15 1
PY2021 Principal investigator $225,668.73 22
PY2020 Recipient $4,613.50 2
PY2020 Principal investigator $142,241.55 25
PY2019 Recipient $75.60 1
PY2019 Principal investigator $432,556.53 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202535039
Principal investigator 1 ABBVIE INC. $6,313.95 12/05/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529434
Principal investigator 1 Dompe Farmaceutici S.p.A. $7,620.00 12/04/2025 Non-covered Recipient Entity
Thomas Jefferson University
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248398913
Principal investigator 1 ABBVIE INC. $33,440.85 11/05/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521919
Principal investigator 1 ABBVIE INC. $17,721.45 10/09/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515541
Principal investigator 1 Novo Nordisk AS $1,500.00 09/17/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213775389
Principal investigator 1 Novo Nordisk AS $1,500.00 09/17/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213784376
Principal investigator 1 Novo Nordisk AS $750.00 09/17/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213829328
Principal investigator 1 ABBVIE INC. $4,674.70 09/08/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202510224
Principal investigator 1 ABBVIE INC. $9,482.55 09/08/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202510226
Principal investigator 1 ABBVIE INC. $33,196.50 09/04/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508708
Principal investigator 1 ABBVIE INC. $18,254.70 08/06/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502751
Principal investigator 1 Eli Lilly and Company $407.00 07/28/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891498
Principal investigator 1 Novo Nordisk AS $2,604.18 07/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213731036
Principal investigator 1 ABBVIE INC. $14,682.60 07/02/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202496467
Principal investigator 1 Novo Nordisk AS $621.00 06/25/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213843887
Principal investigator 1 ABBVIE INC. $16,156.80 06/03/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489507
Principal investigator 1 Novo Nordisk AS $3,350.00 05/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213747112
Principal investigator 1 Novo Nordisk AS $2,550.00 05/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213753471
Principal investigator 1 Novo Nordisk AS $300.40 05/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213755597
Principal investigator 1 Novo Nordisk AS $6.00 05/20/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213754958
Principal investigator 1 ABBVIE INC. $15,970.50 05/07/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482647
Principal investigator 1 Novo Nordisk AS $29.00 04/30/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213732577
Principal investigator 1 Novo Nordisk AS $1,786.68 04/23/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213714857
Principal investigator 1 Abbott Laboratories $8,700.00 04/21/2025 Non-covered Recipient Entity
Thomas Jefferson University
ISM2512001A-A Prospective, Observational Study of the Effectiveness of FreeStyle/FreeStyle Libre 2 in People with Type 2 Diabetes using Basal Insulin No dispute reported 06/30/2026 1248149522
Principal investigator 1 ABBVIE INC. $10,665.00 04/03/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202473364
Principal investigator 1 Novo Nordisk AS $29.00 03/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213766397
Principal investigator 1 Novo Nordisk AS $1,325.20 03/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213803987
Principal investigator 1 Eli Lilly and Company $6,856.00 03/24/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 1187891494
Principal investigator 1 ABBVIE INC. $13,648.50 03/07/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459918
Recipient Eli Lilly and Company $77.45 03/06/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187871439
Principal investigator 1 Novo Nordisk AS $29.00 02/28/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213762944
Principal investigator 1 Novo Nordisk AS $1,890.00 02/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213826735
Principal investigator 1 Dompe Farmaceutici S.p.A. $3,370.00 02/19/2025 Non-covered Recipient Entity
Thomas Jefferson University
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248398915
Principal investigator 1 ABBVIE INC. $15,660.00 02/06/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202446761
Principal investigator 1 Eli Lilly and Company $1,190.36 01/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187891914
Principal investigator 1 Novo Nordisk AS $2,439.22 01/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213819482
Principal investigator 1 Novo Nordisk AS $29.00 01/31/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIV
NN9535-4801 No dispute reported 06/30/2026 1213846487
Principal investigator 1 Eli Lilly and Company $42,281.00 01/21/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187893192
Principal investigator 1 Eli Lilly and Company $68,991.00 01/06/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187893194
Principal investigator 1 Eli Lilly and Company $100,609.00 01/06/2025 Non-covered Recipient Entity
THOMAS JEFFERSON UNIVERSITY
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187893584